In pre‐rituximab era, BCL2 expression was considered a poor prognostic factor in NHL; however, the overexpression of BCL2 in the post‐rituximab era in DLBCL has shown no prognostic value (Mounier et al., 2003). This evidence concerns the gene BCL2 and non-Hodgkin lymphoma.